Evidence map›Paper›PMID 40307941›Full record

ArticleExperimental hematology & oncology2025

Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival.

Jennifer J Gile, Patrizia Mondello, Zixing Wang, Ying Li, Radhika Bansal, Sangeetha Gandhi, Henan Zhang, Elham Babadi, Kodi Martinez, Gabrielle McCoy and 28 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02348216 (A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02348216 phase1 / phase2completednot on this map

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma

TypeinterventionalSponsorKite, A Gilead CompanyRan2015 to 2023Enrolled307ConditionsRefractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)ArmsAxicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Jennifer J Gile *Division of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Patrizia Mondello *Division of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Zixing WangKITE, a Gilead Company, Santa Monica, CA, 90404, USA.
Ying LiDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Radhika BansalDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Sangeetha GandhiDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Henan ZhangDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Elham BabadiDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Kodi MartinezDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Gabrielle McCoyDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Zuoyi ShaoDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Kevin ReganDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Matthew A HathcockDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Panwen WangDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Junwen WangDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Abdullah S Al SalehDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Gordon RuanDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Stephen M AnsellDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
N Nora BennaniDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Patrick B JohnstonDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Jonas PaludoDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Jose C Villasboas-BisnetoDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Arushi KhuranaDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Urshila DuraniDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Yucai WangDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Paul J HampelDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Allison RosenthalDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Javier MunozDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Eider MorenoDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Januario E CastroDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Hemant S MurthyDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Mohamed Kharfan-DabajaDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Saad S KenderianDivision of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA.
Jenny J KimKITE, a Gilead Company, Santa Monica, CA, 90404, USA.
Rhine ShenKITE, a Gilead Company, Santa Monica, CA, 90404, USA.
Mike MattieKITE, a Gilead Company, Santa Monica, CA, 90404, USA.
Yi Lin *Division of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA. Lin.Yi@mayo.edu.
Thomas E Witzig *Division of Hematology, Mayo Clinic, 200 SW First Street, Rochester, MN, 55905, USA. Witzig.thomas@mayo.edu.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
Elucidating the role of IRF4 in reprogramming the tumor microenvironment in follicular lymphomaK08CA279652 · NCI · MAYO CLINIC ROCHESTER · PI Patrizia Mondello · 2024 to 2026
$534k
NCI NIH HHS K08 CA279652NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274NIH/NCI University of Iowa, Mayo Clinic Lymphoma SPORE CA97274
6 · The paper itself

Abstract

backgroundHypomagnesemia has been correlated with inferior outcomes in patients with large B cell lymphoma (LBCL) undergoing stem cell transplants. As T-cell and myeloid cell dysfunction have been associated with low magnesium conditions, we investigated whether serum magnesium (Mg) levels could predict clinical outcomes in LBCL patients who received chimeric antigen receptor T-cell therapy.

methodsPatients with LBCL who received axi-cel under the ZUMA-1 trial or as FDA approved therapy at Mayo Clinic were examined. Serum samples were obtained at specified time points and cytokine analysis was performed. Single cell RNA sequencing was performed on peripheral blood mononuclear cells. The Student T-test, Kruskal Wallis, or Fisher's Exact Tests were used to compare differences in demographics across Mg levels. Survival curves were plotted using the Kaplan-Meier methodology and compared using the Wilcoxon test.

resultsWe found that hypomagnesemia before lymphodepletion chemotherapy predicted inferior progression-free and overall survival in the pivotal study ZUMA-1 (NCT02348216). These results were validated in an independent cohort of LBCL patients receiving axicabtagene ciloleucel (axi-cel) at Mayo Clinic. Hypomagnesemia correlated with increased inflammatory serum markers and cytokine levels including ferritin, IL-6, IL1Ra, IL-8, and MIP1a. scRNAseq analysis unveiled altered immune interactions between monocytes and T cells with a concordant immune suppressive transcriptome.

conclusionsHypomagnesemia at the time of CAR-T infusion is associated with an unfavorable inflammatory profile and decreased response and survival in LBCL patients receiving axi-cel. These findings suggest a potentially actionable prognostic factor for patients with large cell lymphoma undergoing CAR-T.

Indexed as

CAR-TCytokinesLymphomaMagnesiumSurvival analysis

Identifiers

PMID40307941
PMCPMC12044716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.